Moreover, the sensitivity difference of GSK-J4 treatment was also observed in correlation with other key pathways of prostate tumorigenesis in castration-resistant prostate cancer cell lines compared with AR-WT prostate cancer cells, suggesting a AR-dependent involvement of JMJD3 [55]. The gene discussed is KDM6B; the disease is prostate cancer.